EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double‐Blind Randomized Crossover Placebo‐Controlled Trial

Mayumi Shoji, Hisaya Kato, Masaya Koshizaka iD, Hiyori Kaneko, Yusuke Baba, Takahiro Ishikawa, Naoya Teramoto, Daisuke Kinoshita, Ayano Yamaguchi, Yukari Maeda, Yosuke Inaba, Yuki Shiko und 4 weitere

Aging Cell · 2025-08 · 24 (8)

DOI: 10.1111/acel.70093 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Aging Cell, online erschienen am 03.06.2025. Verfasst von Mayumi Shoji und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan. Hauptthemen laut MEDLINE: Niacinamide, Werner Syndrome, Dietary Supplements. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Health, Labour and Welfare Research on Rare and Intractable Diseases Program, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Werner syndrome (WS) is a rare hereditary progeroid syndrome caused by mutations in the WRN gene. Patients frequently develop various age‐associated diseases prematurely, often leading to early mortality (≤ 60 years of age). Depletion of nicotinamide adenine dinucleotide (NAD) + has been reported in patients with WS, suggesting a key role in the pathogenesis of WS. NAD + supplementation may improve the condition of WS and other accelerated aging diseases. Therefore, we conducted a double‐blind, randomized, crossover, placebo‐controlled trial in patients with WS to evaluate the safety and efficacy of the NAD + precursor, nicotinamide riboside (NR). NR (1000 mg) or placebo capsules were self‐administered once daily for 26 weeks, followed by a crossover to the opposite arm for another 26 weeks. The primary endpoint was the safety of NR. Secondary endpoints included NAD + levels in plasma, number, and size of skin ulcers, blood examinations, sarcopenia, heel pad thickness, cardio–ankle vascular index (CAVI), and ankle–brachial index. The exploratory endpoints involved metabolome profiles of plasma. No serious adverse events were observed during NR treatment. Importantly, CAVI improved, the skin ulcer area decreased, and heel pad thinning showed a declining trend. Metabolomic analysis revealed a significant decrease in blood creatinine. NR treatment significantly improved arterial stiffness, as indicated by CAVI, and likely suppressed renal functional decline in patients with WS. Therefore, NR may be beneficial for preventing atherosclerosis, skin ulcers, and kidney dysfunction in patients with WS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NiacinamideWerner SyndromeDietary SupplementsHumansDouble-Blind MethodMaleFemaleCross-Over StudiesMiddle AgedPyridinium CompoundsAdult

Stichwörter der Autor:innen

Werner syndromearterial stiffnesscardio–ankle vascular indexcreatinineintractable skin ulcersmetabolomenicotinamide riboside

Substanzen

Niacinamidenicotinamide-beta-ribosidePyridinium Compounds

Autor:innen und Institutionen

  • Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Division of Diabetes, Department of Medicine, Metabolism and Endocrinology, Chiba University Hospital, Chiba, Japan.
  • Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Center for Preventive Medical Science, Chiba University, Chiba, Japan.
  • Department of General Medical Science, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Department of Metabolism and Endocrinology, Eastern Chiba Medical Center, Togane, Japan.

ORCID-Profile: Masaya Koshizaka, Vilhelm A Bohr

Förderung

  • the Ministry of Health, Labour and Welfare Research on Rare and Intractable Diseases Program
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Ministry of Health Mexico

Zitieren

APA

Shoji, M., Kato, H., Koshizaka, M., Kaneko, H., Baba, Y., Ishikawa, T., Teramoto, N., Kinoshita, D., Yamaguchi, A., Maeda, Y., Inaba, Y., Shiko, Y., Ozawa, Y., Bohr, V. A., Maezawa, Y., & Yokote, K. (2025). Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double‐Blind Randomized Crossover Placebo‐Controlled Trial. Aging Cell, 24(8). https://doi.org/10.1111/acel.70093

Vancouver

Shoji M, Kato H, Koshizaka M, Kaneko H, Baba Y, Ishikawa T, et al. Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double‐Blind Randomized Crossover Placebo‐Controlled Trial. Aging Cell. 2025;24(8). doi:10.1111/acel.70093

BibTeX
@article{Shoji2025,
  author = {Shoji, Mayumi and Kato, Hisaya and Koshizaka, Masaya and Kaneko, Hiyori and Baba, Yusuke and Ishikawa, Takahiro and Teramoto, Naoya and Kinoshita, Daisuke and Yamaguchi, Ayano and Maeda, Yukari and Inaba, Yosuke and Shiko, Yuki and Ozawa, Yoshihito and Bohr, Vilhelm A and Maezawa, Yoshiro and Yokote, Koutaro},
  title = {Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double‐Blind Randomized Crossover Placebo‐Controlled Trial},
  journal = {Aging Cell},
  year = {2025},
  volume = {24},
  number = {8},
  doi = {10.1111/acel.70093}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche